StockPreacher.com Issues Trading Outlook for Neuralstem Inc.

• Press Release
• Source: StockPreacher
• On 6:50 am EDT, Thursday September 24, 2009

DALLAS, Sept. 24, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Neuralstem Inc. (AMEX:CUR - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
ACTC.OB	0.12	+0.01

{"s" : "actc.ob,cur,genz,gern,stem","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report on Neuralstem Inc. (AMEX:CUR - News) should be of particular interest to other companies in the Biotechnology and Drug sectors: Stemcells Inc. (Nasdaq:STEM - News), Genzyme Corp. (Nasdaq:GENZ - News), Geron Corp. (Nasdaq:GERN - News) and Advanced Cell Technologies. (Pink Sheets:ACTC - News).

The full report is available at: http://www.stockpreacher.com/n/CUR

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher

Neuralstem Inc. (CUR) is a biotechnology company focused on developing and commercializing human neural stem-cell technology in the field of regenerative medicine. The Company manufactures its cells both in-house and on an outsource basis. It uses these cells in its research grant and collaborative programs. The Company outsources all the manufacturing and storage of its stem cells to be used in pre-clinical works to Charles River Laboratories Inc., of Wilmington, Massachusetts.

Message Board Search for CUR: http://www.boardcentral.com/boards/CUR

In the report, the analyst notes:

"CUR recently announced that the U.S. Food and Drug Administration has approved its Investigational New Drug application to commence a phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells. CUR is the first company to commence a stem-cell trial to treat ALS. The trial will study the safety of CUR's cells and the surgical procedures and devices required for multiple injections of CUR's cells directly into the grey matter of the spinal cord.

"In June 2009, CUR announced today that Vicis Capital Master Fund has purchased 800,000 shares of CUR common stock at $1.25 per share, reflecting an approximate 20% premium to the closing price of the stock on Monday, June 29. The Company also issued warrants to Vicis to purchase 2.4 million shares of CUR common stock at $1.25 a share, a third of which must be exercised within a year from the date of issuance, a third within three years, and the final third within five years from the date of issuance. CUR plans to use these proceeds for working capital."

To read the entire report visit: http://www.stockpreacher.com/n/CUR

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com